NCT03390296 2023-09-05
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
3 trialsNCT02953561 2020-10-22
Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03699384 2019-02-20
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Withdrawn